The expression levels of the top anti-ACC core targets SLC3A2, BSG, SLC7A5, SLC7A6, LCN2, and SLC7A9 in ACC and normal samples were analyzed using the GEPIA2 database. This evidence concerns the gene SLC3A2 and adrenal cortex carcinoma.